The field of immunotherapy is a work in progress and researchers are now expanding the use of this treatment and doing a better job of identifying the patients that will benefit the most from it.
During the latest Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, interviews Harold J. Burstein, MD, PhD, an oncologist with the Dana-Farber Cancer Institute, about immunotherapy 2.0, which was named the advance of the year by the American Society of Clinical Oncology (ASCO). This is the second year in a row that ASCO named immunotherapy the advance of the year; however, immunotherapy 2.0 acknowledges the expanding use of immunotherapy.
According to Burstein, the report recognizes that immunotherapy is a work in progress and that researchers are now doing a better job of identifying patients and tumor subsets that will benefit the most from this therapy. During the interview, Burstein and Salber also discuss toxicities related to immunotherapy and paying for the treatment.
Listen below or through one of these podcast services: